<DOC>
	<DOCNO>NCT00450892</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel , fluorouracil , epirubicin , cyclophosphamide , work different way stop growth tumor cell , either kill cell stop dividing . Lapatinib may stop growth tumor cell block enzymes need cell growth . Monoclonal antibody , trastuzumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Giving treatment surgery may make tumor small reduce amount normal tissue need remove . Giving trastuzumab surgery may kill tumor cell remain surgery . PURPOSE : This randomized phase I/II trial study side effect best dose docetaxel lapatinib give without combination chemotherapy see well work treat woman locally advance , inflammatory , resectable breast cancer .</brief_summary>
	<brief_title>Phase I/II Study Neoadjuvant Lapatinib Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose neoadjuvant therapy comprise docetaxel lapatinib ditosylate fluorouracil , epirubicin hydrochloride , cyclophosphamide ( FEC chemotherapy ) patient HER2-positive locally advanced , inflammatory , large resectable breast cancer . ( Phase I ) - Determine safety regimen patient . ( Phase I ) - Determine pathological complete response rate patient treat neoadjuvant docetaxel lapatinib ditosylate follow FEC chemotherapy , neoadjuvant docetaxel trastuzumab ( Herceptin® ) follow FEC chemotherapy . ( Phase II ) Secondary - Determine biological activity ( i.e. , change apoptosis proliferation marker [ PTEN mutation function , pAkt , mTOR , associate protein ] ) neoadjuvant docetaxel lapatinib ditosylate patient . ( Phase I ) - Determine adverse event biological modification . ( Phase I ) - Determine tolerability regimens patient . ( Phase II ) - Determine clinical activity regimen . ( Phase II ) - Identify gene may predict response patient treat docetaxel lapatinib ditosylate . ( Phase II ) OUTLINE : This multicenter , open-label , phase I dose-escalation study docetaxel lapatinib ditosylate follow randomized phase II study . Patients enrol phase II portion study stratify institution disease status ( locally advance disease v large operable tumor ) . - Phase I ( complete 5/26/2010 ) : Patients receive docetaxel IV 1 hour day 1 oral lapatinib ditosylate daily day 1-21 . Treatment repeat every 3 week 4 course . Two additional course may give discretion physician . - Cohorts 3-6 patient receive escalate dos docetaxel lapatinib ditosylate maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity ( DLT ) . - Phase I bridge step ( complete 5/26/2010 ) : Patients receive FEC chemotherapy comprise fluorouracil IV 15 minute , epirubicin hydrochloride IV 60 minute , cyclophosphamide IV 60 minute day 1 . Treatment repeat every 3 week 3 course . Patients also receive docetaxel lapatinib ditosylate phase I MTD 3 course . - Cohorts 3-6 patient receive de-escalating dos docetaxel lapatinib ditosylate combination FEC chemotherapy MTD determine . The MTD define dose precede 2 3 2 6 patient experience DLT . - Phase II : Patients randomize 1 3 treatment arm . - Arm I : Patients receive docetaxel lapatinib ditosylate MTD bridge step phase I follow FEC chemotherapy . - Arm II : Patients receive docetaxel IV 60 minute trastuzumab ( Herceptin® ) IV 30-90 minute day 1 , 8 , 15 . Patients receive FEC chemotherapy bridge step phase I . Treatment docetaxel trastuzumab repeat every 3 week 3 course absence disease progression unacceptable toxicity . - Arm III : Patients receive docetaxel IV 60 minute , lapatinib ditosylate MTD bridge step phase I , trastuzumab ( Herceptin® ) IV 30-90 minute day 1 , 8 , 15 . Patients receive FEC chemotherapy bridge step phase I . Treatment docetaxel , lapatinib ditosylate , trastuzumab repeat every 3 week 3 course absence disease progression unacceptable toxicity . All patient undergo surgery remove tumor . Patients may receive trastuzumab every 3 week 1 year . Blood sample collect baseline periodically study pharmacokinetic study . Patients also undergo tumor biopsy baseline periodically study laboratory study . Blood tissue sample analyze quantitative reverse transcriptase polymerase chain reaction biomarker profiling ( HER1-3 , Akt 1-3 , mTOR , RICTOR , RAPTOR , CCND1 , p21 , survivin , PTEN ) , immunohistochemistry , fluorescent situ hybridization ( TopoII , HER2 ) , proteomics . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 150 patient accrue phase II .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm invasive breast cancer meeting follow criterion : Phase I Locally advance inflammatory disease , specify subgroup large operable disease neoadjuvant chemotherapy appropriate , define 1 following : Clinical stage T4ad , N ( inflammatory breast carcinoma : tumor mass , breast enlargement , oedema warmth skin often present mandatory diagnosis ) Any clinical T , N2 N3 ( ipsilateral supraclavicular node ) cT3cN0,1 estrogen receptor ( ER ) cT2cN1 ER cT2cN0 ER negative Presence bilateral breast cancer allow No bone , liver , extensive metastasis Minimal lung , skin , nodal metastasis may allow discretion investigator ( phase I ) Phase II Locally advance inflammatory breast cancer , define 1 following : Clinical T4ad , N ( inflammatory breast carcinoma : tumor mass , breast enlargement , oedema warmth skin often present mandatory diagnosis ) Any clinical T , N2 N3 ( ipsilateral supraclavicular node ) And M0 Bilateral breast cancer allow provide 1 side HER2positive Any large resectable T2 T3 breast cancer , M0 HER2positive disease immunohistochemistry , fluorescent situ hybridization , and/or chromogenic situ hybridization No CNS involvement Two frozen trucuts every core biopsy indicate translational research study Hormone receptor status : Estrogen receptor and/or progesterone receptorpositive negative tumor PATIENT CHARACTERISTICS : Female WHO performance status 02 Hemoglobin &gt; 10.0 g/dL Absolute neutrophil count &gt; 1,500/mm^3 Platelet count &gt; 100,000/mm^3 Bilirubin &lt; 1.5 time upper limit normal ( ULN ) AST ALT &lt; 3 time ULN Creatinine &lt; 1.5 time ULN No malignancy within past 3 year except basal cell squamous cell carcinoma skin carcinoma situ cervix ( phase II ) LVEF normal MUGA ECHO ECG normal Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 2 week prior , , 1 month completion study treatment No current active hepatic biliary disease ( exception patient Gilbert 's syndrome , asymptomatic gallstone , stable chronic liver disease require therapy per investigator assessment ) No serious cardiac illness medical condition within past 6 month include , limited , follow : History document congestive heart failure Highrisk uncontrolled arrhythmias Angina pectoris require antianginal medication Clinically significant valvular heart disease Evidence transmural infarction ECG Poorly control hypertension , define systolic blood pressure ( BP ) &gt; 180 mm Hg diastolic BP &gt; 100 mm Hg Able swallow retain oral medication Accessible repeat dose follow No concurrent grapefruit juice No active uncontrolled infection No serious illness No malabsorption syndrome No medical condition ( i.e. , history chronic alcohol abuse , hepatitis , HIV , and/or cirrhosis ) No psychological , familial , sociological , geographical condition would preclude study participation PRIOR CONCURRENT THERAPY : No prior therapy cancer , include chemotherapy , radiotherapy , hormonal therapy breast cancer ( phase I ) No prior epidermal growth factor receptor HER2targeted therapy antibody therapy ( phase I ) More 10 day since prior concurrent CYP3A4 inducers inhibitor More 14 day since prior concurrent herbal infusion dietary supplement No antacid 1 hour lapatinib ditosylate administration No concurrent investigational therapy anticancer therapy No concurrent prophylactic antibiotic</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>inflammatory breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
</DOC>